Articles related to GLAUCOMA

This activity is designed for optometrists managing ocular hypertension, and participants should be more adept at the following after completing it:

Among non-adherent glaucoma patients surveyed in a cross-sectional study, the most prominent barries to adherence are forgetfulness, poor self-efficacy, beliefs/skepticism about glaucoma, poor knowledge of glaucoma, beliefs/skepticism about medication, difficulty with medication schedule, difficulty with drop administration, life stress, side effects of medication, cost, and mistrust of physician. Here are some pointers from three optometrists on how to deal with these and other issues.

Iyuzeh (latanoprost ophthalmic solution), which will be offered to eyecare professionals in the US in the second half of 2023, is made without any of the preservatives often included in topical ocular treatments, such as benzalkonium chloride (BAK). Iyuzeh has consistently lowered IOP and been shown to be tolerable in numerous trials in the US and Europe. In randomized, controlled clinical studies, Iyuzeh reduced IOP by 3–8 mmHg against 4–8 mmHg by Xalatan (latanoprost ophthalmic solution) at 0.005%, which is preserved with BAK, in patients with open-angle glaucoma or ocular hypertension and mean baseline IOP of 19–24 mmHg.